Our Story

QSAM Biosciences is developing
next generation radiopharmaceuticals
for the treatment of cancer.

QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted, therapeutic radiopharmaceuticals

Our initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical developed by IsoTherapeutics, leaders in the nuclear medicine space who also developed FDA-approved Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. 

CycloSam® was cleared by the FDA to commence clinical trials on patients with both metastatic and pediatric primary bone cancer, and patient enrollment in Phase 1 clinical trials commenced in early 2022.

QSAM received Orphan Drug Designation and Rare Pediatric Disease Designation for CycloSam® in the treatment of osteosarcoma, a devastating form of bone cancer that primarily affects children and young adults.   

Our mission is to treat cancer in children and adults through the development of next-generation radiopharmaceuticals.  We plan to achieve this goal through a commitment to solid science, investments in technology with strong evidence of safety and efficacy, and efficient use of capital resources.  

Leadership

Management Team

Experienced & Results-Driven

Douglas Baum

CEO, Co-Founder,
Director

Bio

C. Richard Piazza, PhD

Exec. Chairman, Co-Founder, Director

Bio
Adam King

Adam King

CFO

Bio

Christopher Nelson

General Counsel, Director

Bio

Barry Sugarman​

Regulatory & Clinincal

Bio

Namrata Chand

VP Operations

Bio

Independent Directors

Charles J. Link, M.D.

Bio

Adriann Sax

Bio

Jeffrey M. Soinski

Bio

Scientific Advisory Board

World-renowned authorities in radiopharmaceuticals

R. Keith Frank, PhD

Bio

Jim Simón, PhD

Bio

Investor Information

Overall Market For Nuclear Medicine Is Expected To Reach US $14 Billion By 20252

Emerging technologies designed to detect and treat diseases like cancer, and the ability to use radiopharmaceuticals to both diagnose and treat disease are the main drivers for this market.

2(Radiotherapeutics and Radiodiagnostics): 2019 MEDraysintell Nuclear Medicine Report & Directory (Equipment): Siemens Healthineers Molecular Imaging